München
10.09.25 | 08:05
1,110 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09:09 | DIAMYD MEDICAL AB: Eurasia to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 2 | Cision News | ||
| 09:00 | Diamyd Medical AB (publ): Eurasia to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 52 | GlobeNewswire (Europe) | The Eurasian Patent Office has informed Diamyd Medical that the patent application protecting the use of insulin-based antigens for the treatment of individuals with type 1 diabetes carrying the HLA... ► Artikel lesen | |
| Fr | DIAMYD MEDICAL AB: ASSET partnership, coordinated by Diamyd Medical, organizes 2[nd] annual Type 1 Diabetes screening conference | 1 | Cision News | ||
| 22.07. | DIAMYD MEDICAL AB: Diamyd Medical releases the full video recording from a panel discussion at the ADA meeting in June | 1 | Cision News | ||
| 25.06. | DIAMYD MEDICAL AB: Quarterly Report 3 24/25 | 2 | Cision News | ||
| 25.06. | Diamyd Medical AB (publ): Quarterly Report 3 24/25 | 131 | GlobeNewswire (Europe) | Precision Medicine for Autoimmune Diabetes
Aiming for Accelerated Market Approval
Autoimmune or Type-1 Diabetes (T1D) is a progressive disease, diagnosed as at least two antibodies to the insulin producing... ► Artikel lesen | |
| 16.06. | DIAMYD MEDICAL AB: Diamyd Medical to participate in two key US diabetes events | 11 | Cision News | ||
| DIAMYD MEDICAL Aktie jetzt für 0€ handeln | |||||
| 19.05. | Diamyd Medical AB (publ): Diamyd Medical appoints Niklas Axelsson as CFO | 145 | GlobeNewswire (Europe) | Niklas Axelsson has been appointed CFO of Diamyd Medical. He will assume his position in August and will also join the management team. Niklas Axelsson brings more than 25 years of experience across... ► Artikel lesen | |
| 15.05. | DIAMYD MEDICAL AB: Adjustment of the number of shares and share capital in Diamyd Medical, receives SEK 1.6 million more than previously communicated | 4 | Cision News | ||
| 05.05. | DIAMYD MEDICAL AB: Diamyd Medical has expanded the recently completed rights issue with a directed new issue of SEK 41.6 million | 8 | Cision News | ||
| 30.04. | DIAMYD MEDICAL AB: Diamyd Medical announces final outcome in oversubscribed rights issue: SEK 224 million | 3 | Cision News | ||
| 30.04. | DIAMYD MEDICAL AB: Diamyd Medical updates the preliminary outcome and will exercise the additional unit issue following the oversubscribed rights issue, raising approximately SEK 224 million | 2 | Cision News | ||
| 29.04. | DIAMYD MEDICAL AB: Diamyd Medical's rights issue has been preliminarily subscribed to 95 percent, thereby raising approximately SEK 198 million | 1 | Cision News | ||
| 28.04. | DIAMYD MEDICAL AB: Last day of the subscription period in Diamyd Medicals rights issue | 1 | Cision News | ||
| 28.04. | DIAMYD MEDICAL AB: Europe to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in autoimmune diabetes | 1 | Cision News | ||
| 25.04. | Diamyd Medical AB (publ): Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears second-to-last safety review ahead of early readout in March 2026 | 165 | GlobeNewswire (Europe) | The independent Data Safety Monitoring Board (DSMB) has completed its fifth scheduled safety review of Diamyd Medical's registrational Phase 3 trial, DIAGNODE-3, evaluating the precision medicine immunotherapy... ► Artikel lesen | |
| 22.04. | DIAMYD MEDICAL AB: Shareholders in Diamyd Medical, including the Chairman of the Board, have provided additional subscription commitments in the ongoing rights issue | 2 | Cision News | ||
| 21.04. | Diamyd Medical AB: Diamyd Medical highlights opportunity in Type 1 Diabetes prevention, adult-onset market, and upcoming Phase 3 readout | 331 | PR Newswire | STOCKHOLM, April 21, 2025 /PRNewswire/ -- In a recent investor interview, Diamyd Medical Board Member Professor Mark Atkinson and CEO Ulf Hannelius shared key insights into the Company's... ► Artikel lesen | |
| 17.04. | DIAMYD MEDICAL AB: The prevention trial DiaPrecise with Diamyd® clears first safety milestone | 1 | Cision News | ||
| 15.04. | Diamyd Medical AB (publ): Australia grants Diamyd Medical patent for novel antigen combination in autoimmune diabetes treatment | 170 | GlobeNewswire (Europe) | The Australian Patent Office has granted a patent protecting a novel immunotherapeutic composition developed by Diamyd Medical for use in the treatment and prevention of autoimmune diabetes. The patent... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 179,00 | -0,44 % | AbbVie, Atai Life Sciences und Neural Therapeutics: Deals im Milliarden-Markt für Psychedelika | ||
| INNOCAN PHARMA | 7,355 | +2,15 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 04.09.2025 | Das Instrument IP4 CA45783P1027 INNOCAN PHARMA CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 04.09.2025 und ex Kapitalmassnahme am 05.09.2025 The instrument IP4 CA45783P1027 INNOCAN PHARMA CORP.... ► Artikel lesen | |
| ABBOTT LABORATORIES | 110,84 | -1,67 % | Research and Markets: Europe Liver Disease Therapeutic Market Analysis Report 2025-2033 Featuring Abbott, Astellas, BMS, Gilead Sciences, GSK, F. Hoffman-La Roche, Merck, Novartis, Sanofi, Pfizer, Takeda - ResearchAndMarkets.com | The "Europe Liver Disease Therapeutic Market Forecast 2025" report has been added to ResearchAndMarkets.com's offering.
The Europe Liver Disease Therapeutic Market is expected to grow from US$... ► Artikel lesen | |
| ARZNEIWERK AG VIDA | 0,159 | 0,00 % | EQS-HV: Arzneiwerk AG VIDA: Bekanntmachung der Einberufung zur Hauptversammlung am 04.09.2025 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: Arzneiwerk AG VIDA
/ Bekanntmachung der Einberufung zur Hauptversammlung
Arzneiwerk AG VIDA: Bekanntmachung der Einberufung zur Hauptversammlung am 04.09.2025 in Berlin... ► Artikel lesen | |
| ZOETIS | 127,86 | -0,11 % | Analyst Expectations For Zoetis' Future | ||
| CRESCO LABS | 1,043 | -2,98 % | Cresco Labs is still undervalued, this analyst says | ||
| CSPC PHARMA | 1,218 | +0,45 % | CSPC Pharmaceutical Group-Aktie mit deutlichen Kursgewinnen (1,221 €) | Zu den großen Gewinnern an der Börse zählt am Mittwoch der Anteilsschein der CSPC Pharmaceutical Group . Der Kurs des Anteilsscheins legt kräftig zu. Ein Wertanstieg auf zwischenzeitlich 1,22 Euro beschert... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 22,400 | +0,90 % | Stocks Moving Premarket: PPCB, BTAI, Tonix Pharmaceuticals, DAY, TPIC, And Other Gainers & Losers | OTTAWA (dpa-AFX) - At 6.50 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| AMARIN | 12,800 | -1,54 % | Amarin Corporation plc: Amarin Reports Second Quarter 2025 Financial Results | -- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 41,000 | -0,97 % | Nektar Therapeutics: Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 | SAN FRANCISCO, Sept. 9, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will present results from the ongoing REZOLVE-AD Phase... ► Artikel lesen | |
| WUXI BIOLOGICS | 4,012 | -3,65 % | Kurs von WuXi Biologics steigt etwas (4,0895 €) | Am Aktienmarkt liegt der Anteilsschein von WuXi Biologics aktuell im Plus. Die Aktie notiert zur Stunde bei 4,09 Euro. Der Anteilsschein von WuXi Biologics verzeichnet derzeit einen Preisanstieg von... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 107,90 | +0,47 % | Axsome Therapeutics auf Morgan-Stanley-Konferenz: Strategisches Wachstum und Innovation im Fokus | ||
| JAGUAR HEALTH | 2,040 | +5,15 % | Jaguar Health, Inc.: Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts | Click here to register SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / September 5, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO,... ► Artikel lesen | |
| DAIICHI SANKYO | 20,680 | -3,72 % | Daiichi Sankyo And Merck: Ifinatamab Deruxtecan Shows Promising Results In Phase 2 ES-SCLC Trial | KENILWORTH (NJ) (dpa-AFX) - Daiichi Sankyo (DSKYF, 4568.T) and Merck & Co Inc. (MRK) announced that Results from the IDeate-Lung01 phase 2 trial showed that ifinatamab deruxtecan (I-DXd) demonstrated... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 20,670 | -2,59 % | Assessing ACADIA Pharmaceuticals: Insights From 12 Financial Analysts |
Das Unternehmen DIAMYD MEDICAL AB kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 1,110 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAMYD MEDICAL AB finden Sie auf Wallstreet Online.